← Back to Search

Care Continuity Program for Opioid Use Disorder

N/A
Waitlist Available
Led By Abraham Hartzema, PhD
Research Sponsored by Sure Med Compliance
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 4 months
Awards & highlights

Study Summary

This study is evaluating whether a tool that helps prescribers identify patients at risk for opioid misuse can improve patient outcomes.

Eligible Conditions
  • Opioid Use Disorder
  • Opioid Abuse
  • Chronic Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 4 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Morphine Milligram Equivalent
Physical Functioning
Prescriber Confidence
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Care Continuity Program + EducationExperimental Treatment1 Intervention
Participating clinics (and their prescribers and patients) will be randomly selected to implement the Care Continuity Program (CCP) intervention, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients will receive welcome letters and be required to complete CCP self-assessments before each appointment. Prescribers will begin using the generated CCP summary page at each appointment to help make decisions about initiating or maintaining an opioid prescription for an individual patient.
Group II: Education AloneActive Control1 Intervention
Participating clinics (and their prescribers and patients) will be randomly selected to the control group, at which time prescribers will view an Accreditation Council for Continuing Medical Education (ACCME) accredited educational video about the safe initiation, continuation, and discontinuation of opioid therapy, as well as the data elements required by law and regulation to be included in the medical records of patients prescribed opioids. Then patients and prescribers will continue treatment as usual in their clinic.

Find a Location

Who is running the clinical trial?

Sure Med ComplianceLead Sponsor
National Institute on Drug Abuse (NIDA)NIH
2,468 Previous Clinical Trials
2,617,509 Total Patients Enrolled
John Bowman, BSStudy DirectorSure Med Compliance

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Comparing a Patient Self-Assessment Software to Treatment as Usual in Opioid Prescriber and Patient Opioid Outcomes
2021. "Comparing a Patient Self-Assessment Software to Treatment as Usual in Opioid Prescriber and Patient Opioid Outcomes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04945525.
~480 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top